Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alpha-1-antitrypsin for progression of COVID-19 in ICU patients
IRCT20110510006431N6Phase 3Completed
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Nov 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Alpha-1-antitrypsin with Placebo (2 arms). Primary endpoints: Serum alpha-1-antitrypsin level, Neutrophil count and 9 more. Started Nov 2022; status: completed.
02
Drugs
alpha-1-proteinase inhibitor
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on IRCT20110510006431N6.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20110510006431N6.